VKTX - Company ID 0001607678
The table below shows Viking Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $150.15M | $89.95M | $60.15M | $41.39M | $22.79M | $23.77M |
Viking Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $13.97M |
| $8.61M |
| $14.42M |
| $14.08M |
| $13.77M |
| $10.29M |
| Operating income | -$164.13M | -$98.56M | -$74.57M | -$55.47M | -$36.56M | -$34.05M |
| Income tax | - | - | - | - | - | - |
| Net income | -$158.32M | -$90.79M | -$65.56M | -$45.63M | -$24.94M | -$22.25M |
| EPS (diluted) | -$1.37 | -$0.81 | -$0.58 | -$0.41 | -$0.22 | -$0.20 |